Celecoxib with immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a pain reliever (celecoxib) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug combination works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer (hepatocellular carcinoma) that has spread or cannot be surgically removed.
- Your cancer is measurable on a CT scan or MRI.
- You are at least 18 years old.
- You are in generally good health (able to do daily activities, with some limitations allowed).
- Your blood counts (platelets, hemoglobin, neutrophils) and liver/kidney function meet certain minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests additional therapies given alongside standard immunotherapy for advanced melanoma or liver cancer. The goal is to see if adding these treatments can make the immunotherapy work better.
This trial tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) with standard chemotherapy (gemcitabine and cisplatin) for a rare type of liver cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether adding celecoxib (an anti-inflammatory pill) to pembrolizumab (an immunotherapy) and chemotherapy helps treat intrahepatic cholangiocarcinoma—a type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than the standard two-drug approach.
This trial tests whether adding a liver-directed treatment to standard systemic therapy can improve outcomes for people with liver cancer that cannot be removed. It may help shrink tumors or slow the disease while on current treatment.
This trial combines an immunotherapy (Envafolimab), a targeted therapy (Suvemcitug), and a special chemotherapy infusion that goes directly into the liver (HAIC) to try to shrink or control advanced liver cancer that can't be removed by surgery. The goal is to help convert the tumor to a state where it might be operable, and to improve long-term outcomes.
This trial tests a combination of two immunotherapy drugs, tremelimumab and durvalumab, for people with advanced liver cancer (HCC) who have moderate cirrhosis (Child-Pugh B). The goal is to see if this treatment can shrink tumors or slow cancer growth.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.